Evaluation of Radiofluorinated Carboximidamides As Potential IDO-targeted PET Tracers for Cancer Imaging

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Feb 5

PMID 28159919

Citations 3

Authors

Xuan Huang

Zhongjie Pan

Michael L Doligalski

Xia Xiao

Epifanio Ruiz

Mikalai M Budzevich

Haibin Tian

Affiliations

Soon will be listed here.

Abstract

IDO1 is an enzyme catalyzing the initial and rate-limiting step in the catabolism of tryptophan along the kynurenine pathway. IDO1 expression could suppress immune responses by blocking T-lymphocyte proliferation locally, suggesting a role of IDO in the regulation of immune responses. The goal of this study was to evaluate the potential of radiofluorinated carboximidamides as selective PET radioligands for IDO1. Specific binding correlated with IDO1 expression as measured through in vitro, microPET experiments. Specific accumulation of the new radiotracer [18F]IDO49 was observed in IDO1-expressing tumors and confirmed by Western blot and IHC analyses. These results suggest that [18F]IDO49 has substantial potential as an imaging agent that targets IDO1 in tumors, and therefore may be utilized as a companion diagnostic for IDO1 targeted therapies.

Citing Articles

Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology-From Bench to Bedside.

Stauff E, Xu W, Kecskemethy H, Langhans S, Kandula V, Averill L Biomolecules. 2025; 15(1).

PMID: 39858441 PMC: 11762981. DOI: 10.3390/biom15010047.

Radiopharmaceuticals and their applications in medicine.

Zhang S, Wang X, Gao X, Chen X, Li L, Li G Signal Transduct Target Ther. 2025; 10(1):1.

PMID: 39747850 PMC: 11697352. DOI: 10.1038/s41392-024-02041-6.

Molecular imaging for cancer immunotherapy.

Lim E, Drake C, Mintz A Immunooncol Technol. 2022; 5:10-21.

PMID: 35756142 PMC: 9216415. DOI: 10.1016/j.iotech.2020.03.001.

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer.

Wierstra P, Sandker G, Aarntzen E, Gotthardt M, Adema G, Bussink J EJNMMI Radiopharm Chem. 2019; 4(1):29.

PMID: 31696402 PMC: 6834817. DOI: 10.1186/s41181-019-0078-z.

References

Smith G, Zhao Y, Leyton J, Shan B, Nguyen Q, Perumal M . Radiosynthesis and pre-clinical evaluation of [(18)F]fluoro-[1,2-(2)H(4)]choline. Nucl Med Biol. 2011; 38(1):39-51. DOI: 10.1016/j.nucmedbio.2010.06.012. View

Koblish H, Hansbury M, Bowman K, Yang G, Neilan C, Haley P . Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 2010; 9(2):489-98. DOI: 10.1158/1535-7163.MCT-09-0628. View

Vacchelli E, Aranda F, Eggermont A, Sautes-Fridman C, Tartour E, Kennedy E . Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2015; 3(10):e957994. PMC: 4292223. DOI: 10.4161/21624011.2014.957994. View

Juhasz C, Nahleh Z, Zitron I, Chugani D, Janabi M, Bandyopadhyay S . Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies. Nucl Med Biol. 2012; 39(7):926-32. PMC: 3443322. DOI: 10.1016/j.nucmedbio.2012.01.010. View

Huang X, Xiao X, Gillies R, Tian H . Design and automated production of 11C-alpha-methyl-l-tryptophan (11C-AMT). Nucl Med Biol. 2016; 43(5):303-8. DOI: 10.1016/j.nucmedbio.2016.02.001. View

Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N . Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003; 9(10):1269-74. DOI: 10.1038/nm934. View

Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C . Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006; 12(4):1144-51. DOI: 10.1158/1078-0432.CCR-05-1966. View

Munn D, Mellor A . Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007; 117(5):1147-54. PMC: 1857253. DOI: 10.1172/JCI31178. View

Jiang T, Sun Y, Yin Z, Feng S, Sun L, Li Z . Research progress of indoleamine 2,3-dioxygenase inhibitors. Future Med Chem. 2015; 7(2):185-201. DOI: 10.4155/fmc.14.151. View

10.

Takikawa O, Kuroiwa T, Yamazaki F, Kido R . Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem. 1988; 263(4):2041-8. View

11.

Juhasz C, Muzik O, Lu X, Jahania M, Soubani A, Khalaf M . Quantification of tryptophan transport and metabolism in lung tumors using PET. J Nucl Med. 2009; 50(3):356-63. PMC: 2784997. DOI: 10.2967/jnumed.108.058776. View

12.

Lob S, Konigsrainer A, Rammensee H, Opelz G, Terness P . Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat Rev Cancer. 2009; 9(6):445-52. DOI: 10.1038/nrc2639. View

13.

Munn D, Shafizadeh E, Attwood J, Bondarev I, Pashine A, Mellor A . Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999; 189(9):1363-72. PMC: 2193062. DOI: 10.1084/jem.189.9.1363. View

14.

Peng Y, Ueng S, Tseng C, Hung M, Song J, Wu J . Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1. J Med Chem. 2015; 59(1):282-93. DOI: 10.1021/acs.jmedchem.5b01390. View

15.

Murray H, Wellner D, Oca M, Granger A, Libby D, Rothermel C . Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun. 1989; 57(3):845-9. PMC: 313187. DOI: 10.1128/iai.57.3.845-849.1989. View

16.

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y . Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005; 11(16):6030-9. DOI: 10.1158/1078-0432.CCR-04-2671. View

17.

Godin-Ethier J, Hanafi L, Piccirillo C, Lapointe R . Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res. 2011; 17(22):6985-91. DOI: 10.1158/1078-0432.CCR-11-1331. View

18.

Ball H, Sanchez-Perez A, Weiser S, Austin C, Astelbauer F, Miu J . Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007; 396(1):203-13. DOI: 10.1016/j.gene.2007.04.010. View

19.

Liu X, Newton R, Friedman S, Scherle P . Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets. 2009; 9(8):938-52. DOI: 10.2174/156800909790192374. View

20.

Huang X, Gillies R, Tian H . Synthesis of [(18) F] 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L): a novel potential PET probe for imaging of IDO1 expression. J Labelled Comp Radiopharm. 2015; 58(4):156-62. PMC: 4655588. DOI: 10.1002/jlcr.3263. View